ContextLogic Inc - Ordinary Shares - Class A
LOGC
Get informed when a big investor buys or sells
+ FollowMarket Cap$254.49M
Close$
$0.00
100% downside
Current Fair Value
100% downsideOvervalued by 100% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $254.49 Million |
|---|---|
| Enterprise Value | $452.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 2.03 |
| Outstanding Shares | 45,730,500 |
Return
| Return on Equity | 2.83% |
|---|---|
| Return on Assets | 2.15% |
| Return on Invested Capital | -2.43% |
Valuation & Multiples
| P/E Ratio | -85.24 |
|---|---|
| PEG | 16.24 |
| Price to Sales | - |
| Price to Book Ratio | 0.57 |
| Enterprise Value to Revenue | 13.98 |
| Enterprise Value to EBIT | -19.6 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$32.40 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$22.48 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.40%▲ 2.23% |
|---|---|
| Total Invested | $4.85M▲ 1828.26% |
| Investors Holding | 2▲ 1.00% |
ESG Score
No data
About LogicBio Therapeutics Inc
39 employees
CEO: Frederic Chereau LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a...